Amylyx Pharmaceuticals Inc. shares climbed 21% to $37.59 on better-than-expected revenue in the latest quarter due to the commercial launch of relyvrio and albrioza.
The biopharmaceutical company’s loss widened to $42.7 million, or 65 cents a share, for the fourth quarter ended Dec. 31, compared to a loss of $28.3 million, or $4.10 a share, a year earlier. Analysts polled by FactSet expected a loss of 82 cents a share.
Amylyx posted revenue of $21.9 million compared to no revenue in the year-ago period. Analysts polled by FactSet expected $4.7 million.
Amylyx said revenue was attributable to sales of relyvrio in the U.S. and albrioza in Canada.
“Our commercial launch is off to a strong start, and we are encouraged by the engagement we have seen from physicians, people living with ALS, and payors,” said co-Chief Executives Joshua Cohen and Justin Klee.
Shares, which closed up 1.7% to $31.17, are up about 20% over the last 12 months.
